Today: 7 February 2026
Subscribe
Browse Category

Healthcare Stocks News 6 December 2025 - 13 December 2025

McKesson Stock Forecast: MCK Rebounds to $813.80 After Barclays’ Overweight Call — What to Watch Next Week (Updated Dec. 12, 2025)

McKesson Stock Forecast: MCK Rebounds to $813.80 After Barclays’ Overweight Call — What to Watch Next Week (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) McKesson Corporation (NYSE: MCK) ended the week on a steadier footing after an early-week dip, closing Friday at $813.80. The stock is still down roughly 9% from its late-November 52‑week high ($895.58 on Nov. 26), but it remains one of healthcare’s stronger large-cap performers in 2025 as investors continue to reward its specialty-drug and oncology momentum, capital returns, and portfolio reshaping narrative. MarketWatch+1 Below is a detailed recap of what moved McKesson stock this week, the latest company and analyst developments, and the key catalysts traders are watching in the week ahead.
13 December 2025
·····
HCA Stock Outlook: HCA Healthcare (NYSE: HCA) Ends the Week Near $485 After a Volatile Swing — Latest News, Forecasts, and the Week Ahead (Updated Dec. 12, 2025)

HCA Stock Outlook: HCA Healthcare (NYSE: HCA) Ends the Week Near $485 After a Volatile Swing — Latest News, Forecasts, and the Week Ahead (Updated Dec. 12, 2025)

Updated: December 12, 2025 (U.S. market close)HCA Healthcare, Inc. (NYSE: HCA) closed Friday at $484.77, finishing the week essentially flat—but not quiet. A sharp midweek drop and quick rebound put policy risk, reimbursement headlines, and year-end positioning back in the spotlight for America’s largest for-profit hospital operator. StockAnalysis+2MarketWatch+2 Below is what moved HCA stock this week, the most important HCA Healthcare news from the past several days, what analysts are forecasting now, and the key catalysts to watch in the week ahead. HCA stock this week: flat finish, big intrawEEK volatility HCA ended Friday (Dec. 12) at $484.77, up 0.50%
13 December 2025
·····
Stryker (SYK) Stock This Week: Dividend Hike, New COO, FDA Recall Watchlist — Outlook for the Week Ahead (Updated Dec. 12, 2025)

Stryker (SYK) Stock This Week: Dividend Hike, New COO, FDA Recall Watchlist — Outlook for the Week Ahead (Updated Dec. 12, 2025)

Stryker Corporation (NYSE: SYK) closed Friday, December 12, 2025, at $354.09, finishing the session up 0.32% and stabilizing after a choppy stretch that began with a sharp selloff early in the week. Investing.com+1 Stryker is a global medical technology company spanning MedSurg, Neurotechnology and Orthopaedics, with products used across a wide range of procedures worldwide. Stryker Investors Below is a detailed, publication-ready breakdown of what moved Stryker stock this week, the fresh headlines investors are watching, and the catalysts that could matter next week. Stryker stock performance recap (week ending Dec. 12, 2025) After closing the prior week (Dec. 5)
13 December 2025
·····
Centene (CNC) Stock News, Forecasts and Analysis on December 12, 2025: Why Shares Rebounded Near $40 and What Comes Next

Centene (CNC) Stock News, Forecasts and Analysis on December 12, 2025: Why Shares Rebounded Near $40 and What Comes Next

Updated: December 12, 2025 Centene Corporation (NYSE: CNC) is ending 2025 with investors focused on a familiar mix of catalysts: Medicaid margin repair, ACA Marketplace volatility, and Washington policy risk. The stock’s latest pop has been driven by a fresh analyst price-target increase, but the broader narrative remains shaped by a dramatic mid-year guidance reset and ongoing uncertainty around Affordable Care Act premium subsidies that are scheduled to expire December 31, 2025. MarketBeat+2Reuters+2 Below is a detailed, news-style breakdown of what’s driving Centene stock right now, the latest analyst forecasts, and the key risks and signposts investors are watching as
12 December 2025
····
Centene (CNC) Stock Jumps on Baird Upgrade: What December 11, 2025 Means for the Outlook and Forecasts

Centene (CNC) Stock Jumps on Baird Upgrade: What December 11, 2025 Means for the Outlook and Forecasts

Centene Corporation (NYSE: CNC) has snapped back into the spotlight. On December 11, 2025, Centene stock surged above $40 after Robert W. Baird lifted its price target from $28 to $36 while maintaining a neutral rating. The move added to a sharp multi-week rebound following a brutal summer of guidance cuts, goodwill impairments and a rare quarterly loss. MarketBeat+1 At Thursday’s close, CNC traded around $40.73, up roughly 5.3% on the day, with an intraday high near $40.90. MarketBeat That rally puts shares about 62% above their 52‑week low of $25.08, but still roughly 39% below the 52‑week high of
11 December 2025
·····
Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson stock has gone from sleepy blue chip to market star in 2025. As of the morning of December 11, 2025, JNJ trades around $208 per share, sits at an estimated $500+ billion market capitalization, and is at its 52‑week high after a powerful rally that has outpaced the S&P 500. StockAnalysis+1 Since November 21, 2025, the story around Johnson & Johnson has been driven by three big themes: Below is a detailed, news‑driven look at Johnson & Johnson stock, recent catalysts, risks and the current Wall Street forecast as of December 11, 2025. JNJ stock today: price,
11 December 2025
·····
HeartBeam (BEAT) Stock Soars After FDA Clearance: Latest News, Forecasts and Analyst Views

HeartBeam (BEAT) Stock Soars After FDA Clearance: Latest News, Forecasts and Analyst Views

As of December 11, 2025, HeartBeam, Inc. (NASDAQ: BEAT) has abruptly moved from obscure micro‑cap to one of the hottest tickers in medtech, after winning a pivotal U.S. FDA clearance for its cable‑free, at‑home 12‑lead ECG synthesis software. The stock closed at $1.55 on December 10, up roughly 92% from the prior close of $0.81, with trading volume exploding to more than 270 million shares, versus an average in the low millions. StockAnalysis+1 Around midday on December 11, BEAT was still trading near that level, giving the company a market capitalization of roughly $53 million. StockAnalysis Below is a breakdown
11 December 2025
·····
Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025)

Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025)

Biotech investors faced a dense catalyst calendar on Tuesday, December 9, 2025, as new U.S. Food and Drug Administration (FDA) signals on cell and gene therapy, fresh designations in hematologic cancers and high‑impact clinical data from the American Society of Hematology (ASH) meeting collided with a wave of secondary offerings. Despite a string of double‑digit movers, the sector finished in the red. The iShares Nasdaq Biotechnology ETF (IBB) closed around $167, down roughly 1.6% on the day, while the SPDR S&P Biotech ETF (XBI) slid about 1.8%. By contrast, the SPDR S&P 500 ETF (SPY) was essentially flat and the
9 December 2025
··
Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems, Inc. (NYSE: INSP), a leading developer of implantable devices to treat obstructive sleep apnea, is back in the spotlight. As of December 9, 2025, the stock is trading near the upper end of its recent rebound, supported by strong third-quarter results, favorable reimbursement changes, and a series of analyst upgrades—while simultaneously facing a fresh class-action investigation and lingering questions about growth and valuation. investors.inspiresleep.com+1 INSP stock on December 9, 2025: price action and recent volatility On December 9, 2025, Inspire Medical Systems shares are changing hands at about $141.72, down slightly on the day after touching an
9 December 2025
·····
UnitedHealth Group (UNH) Stock: 2026 Comeback Hopes After a Brutal 2025 – What Investors Need to Know Today (December 8, 2025)

UnitedHealth Group (UNH) Stock: 2026 Comeback Hopes After a Brutal 2025 – What Investors Need to Know Today (December 8, 2025)

UnitedHealth Group (NYSE: UNH) stock is trading in the low‑$300s after a year of surging medical costs, a record‑breaking cyberattack and fresh DOJ scrutiny. With raised 2025 EPS guidance, a 2.7% dividend yield and Wall Street seeing mid‑teens upside, is UNH setting up for a 2026 recovery—or more pain? Quick snapshot (as of December 8, 2025) UnitedHealth (UNH) stock today: price, performance and ex‑dividend date UnitedHealth Group remains one of the most important stocks in the U.S. health‑care ecosystem and a heavyweight in the Dow Jones Industrial Average. But 2025 has been a punishing year. Today is also a key
8 December 2025
····
UnitedHealth Group (UNH) Stock: What to Know Before the Market Opens on December 8, 2025

UnitedHealth Group (UNH) Stock: What to Know Before the Market Opens on December 8, 2025

Published: December 7, 2025 UnitedHealth Group Incorporated (NYSE: UNH) heads into Monday’s U.S. session still in “repair mode” after one of the most bruising years in its modern history. Yet fresh analyst upgrades, stabilizing fundamentals and a key dividend date on December 8, 2025 mean the stock could be more active than usual at the open. Below is a concise, news-driven briefing on UnitedHealth stock before the market opens on December 8 – based on the latest coverage, forecasts and analyses through December 7, 2025. 1. UnitedHealth stock snapshot heading into December 8 For context, Investing.com and FinanceCharts both highlight
7 December 2025
·····
UNH Stock Outlook on December 6, 2025: Can UnitedHealth’s Turnaround Power a 2026 Rebound?

UNH Stock Outlook on December 6, 2025: Can UnitedHealth’s Turnaround Power a 2026 Rebound?

Published: December 6, 2025 — Informational, not investment advice. UnitedHealth Group’s stock (NYSE: UNH) heads into the weekend trading around $330.91 per share, after a choppy week where it helped drive both rallies and sell-offs in the Dow Jones Industrial Average.StockAnalysis Despite a modest bounce from its spring lows, UNH remains one of 2025’s biggest laggards in the S&P 500, still down roughly a third this year and more than 40% below its late‑2024 peak above $600.Trefis+1 The big question for investors now is simple but uncomfortable: Has the bad news finally been priced in, or is UNH still in
6 December 2025
····
1 2 3 4 5 6

Stock Market Today

Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

7 February 2026
Amazon shares fell Friday after the company announced a $200 billion AI infrastructure plan for 2026, exceeding analyst expectations and reviving investor concerns about profitability. Combined 2026 capex flagged by Amazon, Alphabet, Microsoft, and Meta now tops $630 billion. Nvidia, AMD, and Broadcom shares surged on the news, while software and data firms remained under pressure.
Go toTop